Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) has successfully administered the final dose of its lead drug candidate, OCT461201, as part of its phase I clinical trial. The company confirmed that no adverse effects were observed during the trial.
Conducted in the United Kingdom by Simbec Research, the trial employed a single ascending dose protocol.
The final dose was administered on 20 September 2023, aligning with the company's previously announced schedule.
The primary aim of the trial is to establish the safety and tolerability of OCT461201, while also gathering key data on its pharmacological properties.
The company anticipates releasing results by 16 October.